UK Markets open in 6 hrs 25 mins
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • CRUDE OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD FUTURES

    1,782.10
    +21.40 (+1.22%)
     
  • DOW

    34,580.08
    -59.71 (-0.17%)
     
  • BTC-GBP

    38,136.92
    +1,398.20 (+3.81%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • ^FTAS

    4,059.32
    -4.57 (-0.11%)
     

Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Biotest AG / Key word(s): Statement
05.11.2021 / 09:46
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

Dreieich, 5 November 2021. Today, the Management Board and the Supervisory Board of Biotest AG ("Biotest") have published their joint reasoned statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz) on the offer document of GRIFOLS, S.A. ("Bidder") dated 26 October 2021. The Biotest works council has given its own statement, which has been published as an annex to the statement of the Management Board and the Supervisory Board.

In this statement, the Management Board and the Supervisory Board recommend, after a careful review process, to the shareholders to accept the offer. This recommendation is explained in more detail in the joint reasoned statement.

After a thorough review, the Management Board and the Supervisory Board have independently come to the conclusion that the consideration offered by the Bidder is fair within the meaning of Section 31 para. 1 WpÜG and that the implementation of the offer is in the interest of Biotest and its shareholders. In assessing the adequacy of the offer from a financial point of view, the Management Board and the Supervisory Board of Biotest were advised by Rothschild & Co. Rothschild & Co concludes in its Fairness Opinion that the offer is fair to Biotest shareholders from a financial point of view.

The Management Board and the Supervisory Board of Biotest see in the business combination a concrete opportunity to combine the existing resources of the Bidder and Biotest in the field of blood plasma in order to achieve a greater availability of resources as well as a larger product range. The Bidder's intended increase of available resources for Biotest's research and development departments could also drive product development and manufacturing faster than would be possible for Biotest as an individual company.

The complete joint reasoned statement of the Management Board and the Supervisory Board of Biotest can be accessed on the company's website at the following link under the heading Investor Relations (in the section "Takeover offer"):

https://www.biotest.com

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


05.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Biotest AG

Landsteinerstraße 5

63303 Dreieich

Germany

Phone:

0 61 03 - 8 01-0

Fax:

0 61 03 - 8 01-150

E-mail:

investor_relations@biotest.de

Internet:

http://www.biotest.de

ISIN:

DE0005227235, DE0005227201

WKN:

522723, 522720

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1246482


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting